Search company, investor...
Cellix company logo


Founded Year



Grant | Alive

Total Raised


Last Raised

$60K | 6 yrs ago

About Cellix

Cellix provide the researcher with reliable tools to mimic physiological flow conditions in vitro, ensuring laminar flow with highly controlled shear stresses. Adhesion on purified ligands or endothelial cells can be studied, using different cell suspension or even whole blood, providing important insights on drug effectiveness, disease development, adhesion mechanisms in inflammation.

Headquarters Location

Unit 1 Longmile Business Park Longmile Road

Dublin, 12,


+353-1-4500 155

Missing: Cellix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cellix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Cellix Patents

Cellix has filed 1 patent.

The 3 most popular patent topics include:

  • Amines
  • Stereochemistry
  • Enantiopure drugs
patents chart

Application Date

Grant Date


Related Topics




Stereochemistry, Enantiopure drugs, Amines, Benzamides, Animal fungal diseases


Application Date


Grant Date



Related Topics

Stereochemistry, Enantiopure drugs, Amines, Benzamides, Animal fungal diseases



Latest Cellix News

Cellix Biosciences Completes Pre-IND Meeting with FDA on CLX-103 for Ulcerative Colitis

Oct 29, 2018

October 29, 2018 02:00 PM Eastern Daylight Time NEWARK, N.J.--( BUSINESS WIRE )--Cellix Biosciences Inc. (“Cellix Bio”), a development-stage pharmaceutical company, today announced successful completion of a Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the development of CLX-103, a novel molecular conjugate of mesalamine for the treatment of mild to moderate ulcerative colitis. CLX-103 is designed to specifically target the release of mesalamine within the lower gastrointestinal tract. This will potentially allow local exposure to mesalamine, while minimizing systemic exposure to potentially reduce the known side effects of mesalamine. At the Pre-IND meeting, Cellix Bio received guidance for the development of CLX-103 and, accordingly, Cellix Bio plans to submit its IND application by the second quarter of 2019. Mahesh Kandula, Founder, Cellix Bio India, stated, “We are excited by the responses we have received from the FDA for the development of this novel prodrug of mesalamine. We believe it has the potential to improve the therapeutic profile mesalamine for the treatment of ulcerative colitis.” Cellix Bio has engaged Dr. Frank Diana (Chemistry, Manufacturing and Controls) and Dr. Mudher Albassam (Non-clinical) to bolster its pipeline development team. Cellix Bio also has engaged Camargo Pharmaceutical Services, LLC, to lead the regulatory and strategic development of CLX-103 in the United States. About Cellix Biosciences Cellix Bio is an innovative biopharmaceutical company founded by Mahesh Kandula, innovator of SynergixTM technology, and Subbu Apparsundaram. Cellix Bio focuses on improving the therapeutic profile of existing drugs for improved treatment outcome for patients. Cellix Bio works closely with the scientific community, universities and research institutions to advance and build the value of SynergixTM technology, develop promising intellectual property, and create value for its stakeholders and investors. Cellix Bio aims to develop a robust pipeline of new medicines addressing unmet medical needs across diverse therapeutic areas. For more information on Cellix Bio, visit . About Camargo Pharmaceutical Services Camargo is the preferred partner for the ideation, development, and approval of advanced medicines that help people live a better life. Camargo offers a full portfolio of pharmaceutical services from concept through commercialization to improve medicines. Camargo’s global reach and client base extends to more than 32 countries. Camargo is headquartered in Cincinnati, Ohio. For more about Camargo Pharmaceutical Services, visit .

Cellix Frequently Asked Questions (FAQ)

  • When was Cellix founded?

    Cellix was founded in 2004.

  • Where is Cellix's headquarters?

    Cellix's headquarters is located at Unit 1 Longmile Business Park, Dublin.

  • What is Cellix's latest funding round?

    Cellix's latest funding round is Grant.

  • How much did Cellix raise?

    Cellix raised a total of $60K.

  • Who are the investors of Cellix?

    Investors of Cellix include Horizon 2020, Investec Ventures, Enterprise Ireland and OTC Agregator.

  • Who are Cellix's competitors?

    Competitors of Cellix include ViaCyte, DiscoveryBioMed, Fluxion Biosciences, BioNano Genomics, IRX Therapeutics and 9 more.

Compare Cellix to Competitors

Medicor Biosciences

Medicor Biosciences, founded in 2006 is a development-stage company focused on drug discovery for combating cancer. The founding scientists are leaders in a class of anti-hormone drugs that are designed to block the relaxin hormone cellular signaling pathways in a number of different cancer types. Using the company's Relaxofen technology platform, therapeutic candidates are generated by engineering the natural relaxin peptide to display antagonistic properties. Through pre-clinical development and clinical trials, Medicor Biosciences plans to develop and potentially license the technology so that the therapeutics can be available for cancer patients as an anti-hormone therapy to impair the growth and spread of the disease.

Sword Diagnostics

Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.


VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.

Transposagen Biopharmaceuticals

Transposagen Biopharmaceuticals produces genetically modified MutaRat Knockout Animal Models of human diseases for drug discovery and development. Per the company, the production of animal models is a $1.2 billion/year market and is expected to grow 12 percent annually through 2010.


Acucela Inc. is a biotech company discovering drug therapies for eye diseases. Neurodegenerative retinal diseases such as macular degeneration, Stargardt's disease, retinitis pigmentosa and glaucoma, affect quality of life for over 50 million people worldwide per the company.

Terpenoid Therapeutics

Terpenoid Therapeutics is a drug discovery and development company focused on treatments for cancer. The company are developing a portfolio of small molecule- based compounds primarily for treatment of prostate, brease, brain, lung and colon cancers.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.